MedPath

The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis

Not Applicable
Recruiting
Conditions
Spinal Metastases
Surgery
Lung Cancer
Blood Transfusion Complication
Autologous Blood Transfusion
Interventions
Procedure: Autoblood transfusion
Registration Number
NCT06244264
Lead Sponsor
Guangdong Provincial People's Hospital
Brief Summary

The goal of this single-center prospective randomized controlled trial is to test and compare the safety and effectiveness of autologous blood transfusion in spinal surgery for lung cancer spinal metastases. The main questions it aims to answer are:

* Does autologous blood transfusion increase the incidence of new metastases?

* Does autologous blood transfusion affect postoperative hemoglobin levels and the number of circulating tumor cells in the blood?

* Can autologous blood transfusion reduce the rate of allogeneic transfusion during and after surgery for spinal metastases?

Detailed Description

In this study, participants underwent standard open spinal decompression surgery, and when blood transfusion was needed, autologous blood transfusion or allogeneic blood transfusion was used. Participants will be patients with lung cancer spinal metastases. Investigators will use flow cytometry, immunohistochemistry, and tumor cell culture methods to measure the number of circulating tumor cells in the blood before and after autologous blood transfusion.

Investigators will compare participants who receive autologous blood transfusion with those who do not to observe if there are differences in:

* The incidence of new metastases

* The rate of allogeneic transfusion during and after surgery

* Postoperative hemoglobin levels

* The number of circulating tumor cells in the blood

* The cost associated with transfusion

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
118
Inclusion Criteria
  • The age range is 18-75 years old;
  • The pathological diagnosis was lung cancer and spinal metastatic tumor;
  • Expected survival > 3 months, can tolerate surgery;
  • Unstable spine; And/or spinal cord nerve compression, nerve function; Progressive decline, palliative spinal open decompression surgery
  • Patients with intraoperative/postoperative Hb<90 g/L or other conditions requiring blood transfusion
Exclusion Criteria
  • Serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders;
  • Severe renal insufficiency or need hemodialysis treatment;
  • Sepsis or septicemia;
  • Unable to obtain consent from the patient or family.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Autoblood transfusion + leukocyte filter groupAutoblood transfusionIn our department open surgery is considered as the standard procedure. The patients underwent open surgery, with autologous blood transfusion combined with a leukocyte filter. Blood transfusion based on bleeding during surgery.
Primary Outcome Measures
NameTimeMethod
Intraoperative and postoperative allogeneic blood transfusion rateThrough study completion, an average of 1 year

The number of allogeneic blood transfusion patients (Intraoperative or postoperative )/ the total number of patients

Secondary Outcome Measures
NameTimeMethod
Incidence of transfusion related adverse reactionswithin 14 days post-surgery

the number of adverse reactions/ the total number of patients

occurence of new lesionsthrough study completion, an average of 1 year

the number of patients with occurence of new lesions / the total number of patients

Number of circulating tumor cells in the bloodwithin 30 days post-surgery

Number of circulating tumor cells in the blood

Trial Locations

Locations (1)

Guangdong provincial people's hospital

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath